AWTTC secures £3.3million in funding to strengthen horizon scanning, data capture, and medicines access

2 December 2024

The All Wales Therapeutics and Toxicology Centre (AWTTC) has secured funding of £3.3 million from the Voluntary Scheme for Medicines Pricing, Access, and Growth (VPAG) Investment Programme.

The VPAG Programme was agreed by the UK Government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) and funding will be available over a five-year period to support a number of important workstreams.

The aim of the VPAG Investment Programme is to enable patients to access the latest treatments more consistently, to strengthen the UK’s global competitiveness in advanced healthcare, technology, clinical research and promote better patient outcomes for a healthier population. 

AWTTC will focus on four key areas to improve the access, implementation, and monitoring of clinically and cost-effective medicines in Wales. These areas are:

1. Horizon scanning and financial forecasting
2. Improved assessment methods and processes for the access of medicines
3. More effective data capture and visualisation to support decision making and better medicines optimisation
4. Enhanced support of post-assessment uptake (implementation) of new medicines

Dr Andrew Champion, AWTTC Programme Director, said: “AWTTC is delighted to receive this significant investment, which will help facilitate access to medicines in Wales and improve outcomes for patients.

“I would like to thank all AWTTC staff for their support in securing this funding which is a landmark achievement for Wales.”

For more information on VPAG visit 2024 voluntary scheme for branded medicines pricing, access and growth - GOV.UK (www.gov.uk)